article thumbnail

Video: Velocity Site Tour

Velocity Clinical Research

Standard Velocity site features: Private exam rooms Comfortable patient reception areas Facilities for extended-stay PK studies Ample parking Secure monitoring rooms and workstations equipped with phones and high-speed internet Individual and secure workstations for research staff Regulatory document processing area EDC capabilities Secure record storage (..)

article thumbnail

World Cancer Day 2024: Trends in Oncology Research and More

XTalks

Innovations in Cancer Therapy CRISPR/Cas9, a groundbreaking gene-editing technology, has demonstrated significant potential in oncology, offering new avenues for cancer treatment. By editing these genes, researchers can effectively neutralize their cancer-promoting effects.

Research 118
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA approves Phase III cerebral Adrenoleukodystrophy trial

Drug Discovery World

The NEXUS interim analysis showed that after 24 weeks of treatment all patients were clinically stable and, radiologically, demonstrated disease arrest or lesion growth stabilisation. Radiological changes were similar to those attained with Hematopoietic Stem Cell Transplant (HSCT) or ex-vivo gene therapy.

article thumbnail

UTMB and HDT Bio receive US funding for vaccine development

Pharmaceutical Technology

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies. By Cytiva Thematic.

article thumbnail

AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3

Delveinsight

OCA-B, or B cell-specific Oct1/2 coactivator, binds to and controls about 150 genes involved in a process through which T cells are reactivated upon reencountering antigens they have earlier identified and memorised. UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3.

article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

article thumbnail

Ginkgo Bioworks awarded DARPA contract for therapeutic proteins 

Drug Discovery World

Ginkgo’s synthetic biology platform, coupled with its extensive expertise in iterative Design–Build–Test–Learn-driven biological engineering, enables the rapid prototyping, optimisation, and development of proteins, enzymes, metabolic pathways, and whole organisms under commercial-scale manufacturing conditions processes.

Protein 52